Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
Phase I Dose-Escalation /Phase II Monocentric Open Trial for Evaluation of Safety and Efficacy of Intracavitary Cisplatin-Fibrin Localized Chemotherapy After Pleurectomy/Decortication or Extrapleural Pneumonectomy for the Treatment of Patients With Malignant Pleural Mesothelioma
Sponsor: Swiss Accident Insurance Fund SUVA
A PHASE1/PHASE2 clinical study on Malignant Pleural Mesothelioma, this trial is completed. The trial is conducted by Swiss Accident Insurance Fund SUVA and has accumulated 8 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Jun 2018 — Jun 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Swiss Accident Insurance Fund SUVA
- Swiss National Science Foundation
- University of Zurich
For direct contact, visit the study record on ClinicalTrials.gov .